A federal judge has rejected standing challenges brought by numerous pharmaceutical companies in an attempt to dismiss several antitrust and consumer protection class action claims leveled by entities that either purchased or resold generic drugs at allegedly inflated prices, reported Law.com
The defendants, which consist of 25 pharmaceutical companies, had argued that plaintiffs did not have standing to bring claims based on state laws in jurisdictions where the class representatives did not either purchase or resell the drugs at issue. Specifically, the defendants contended the plaintiffs did not have Article III standing to bring the claims.
US District Judge Cynthia Rufe of the Eastern District of Pennsylvania, in her 48-page decision from Feb. 15, said the U.S. Court of Appeals for the Third Circuit “has not definitively answered” the question of how courts should balance the interplay between Article III standing and class standing. However, Rufe said the plaintiffs’ allegations showed a “substantial and shared interest” in proving the alleged misconduct in the states outlined in the complaints.
The consolidated multidistrict litigation In re Generic Pharmaceuticals Pricing Antitrust Litigation stems from a wide-ranging federal probe that in 2016 led two pharmaceutical executives to plead guilty to price-fixing charges.
Featured News
T-Mobile Faces Class-Action Lawsuit Over Sprint Merger After Appeal Denied
May 16, 2024 by
CPI
Google Faces Backlash Over Introduction of AI-Generated Summaries in Searches
May 16, 2024 by
CPI
CMA Launches Phase 2 Probe into AlphaTheta’s Acquisition of Serato
May 16, 2024 by
CPI
NFL Executive Escapes Testifying in High-Stakes Trial Over Televised Games
May 16, 2024 by
CPI
EU Consumers Lodge Complaint Against Chinese Retailer Temu Over Content Rules Breach
May 16, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI